Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
BioSpace
The acquisition of Tubulis GmbH--Gilead Sciences' latest of the year after buying Arcells and Ouro Medicines--brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-st
pharminent
April 7, 2026 (Last updated: April 7, 2026)
BioSpace
The acquisition of Tubulis GmbH–Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines–brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-st
